Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment
- First Posted Date
- 2010-01-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 302
- Registration Number
- NCT01043029
ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
Phase 3
Completed
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2009-12-31
- Last Posted Date
- 2014-11-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 584
- Registration Number
- NCT01041404
A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2009-12-17
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 54
- Registration Number
- NCT01034397
A Pharmacokinetic Study of CellCept (Mycophenolate Mofetil) Versus Mycophenolate Sodium in Kidney Transplant Patients
- First Posted Date
- 2009-12-17
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT01033864
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2009-12-17
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 317
- Registration Number
- NCT01034137
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain
- First Posted Date
- 2009-12-16
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 102
- Registration Number
- NCT01032837
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: COPEGUSDrug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2009-12-16
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 59
- Registration Number
- NCT01033448
- Locations
- 🇮🇱
Holy Family Medical Center; Gastroenterology, Nazareth, Israel
🇮🇱Haemek Hospital; Gastroenterology, Afula, Israel
🇮🇱Clalit City Ashdod MC; Liver Clinic, Ashdod, Israel
A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza
- First Posted Date
- 2009-12-16
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT01033734
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 452
- Registration Number
- NCT01026142
- Locations
- 🇧🇪
UZ Brussel, Brussel, Belgium
🇭🇰Queen Mary Hospital; Surgery, Hong Kong, Hong Kong
🇷🇺Semashko Central Clinical Hospital; Dept of Chemotherapy, Moscow, Russian Federation
A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection
Phase 2
Completed
- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- Drug: PlaceboDrug: RO5217790
- First Posted Date
- 2009-12-01
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 206
- Registration Number
- NCT01022346
© Copyright 2025. All Rights Reserved by MedPath